科技创新铸就核心实力，抗肿瘤产品组合企稳领先地位 在本次浦江泌尿肿瘤学术大会上，远大医药联合多方学术力量，正式发布"四基因联检尿路上皮癌早筛早诊项目"，该项目面向尿路上皮癌诊断、随访、疗效 评估等关键场景，推动无创、便捷、可重复的分子检测进入日常临床路径，其四基因联检拥有基因突变+甲基化双重检测机制、补足传统方法盲区的卓越检 出性能、无创便捷，以及高级别证据导向等技术要点——相关注册临床研究已发布在国际权威期刊《Molecular Cancer》，并成功纳入《中国临床肿瘤学会 (CSCO)尿路上皮癌诊疗指南2024》及《膀胱癌早诊早治专家共识(2024年版)》，获得国内外专业权威认可。 公司表示，未来将持续深耕分子诊断、精准诊疗与核药研发三大核心领域，并依托全球核药等创新资源与自主研发体系，致力于打造泌尿肿瘤诊疗一体化解 决方案。 智通财经APP获悉，近日，浦江泌尿肿瘤学术大会暨上海市抗癌协会泌尿肿瘤专委会年会在上海举行，国内外泌尿肿瘤领域顶尖专家齐聚一堂，远大医药 (00512)在会上重磅发布"尿路上皮癌早筛早诊项目"，并带来专题报告《尿路上皮癌精准诊疗与泌尿肿瘤核药研发进展》，集中展示公司在早筛早诊、精准 ...

Core Insights - Company reported record revenue of approximately HKD 6.11 billion for the first half of 2025, with innovative and barrier products accounting for about 51% of total revenue, a year-on-year increase of nearly 15 percentage points [1] - Net profit for the period was approximately HKD 1.17 billion, with a year-on-year revenue growth of about 13% after excluding the impact of centralized procurement and exchange rates [1] - The company achieved significant milestones in its research and development efforts, with total investment in R&D and projects amounting to approximately HKD 1.02 billion, resulting in 38 major milestone advancements [1] Nuclear Medicine Segment - As a leader in nuclear medicine, the company achieved impressive performance in the nuclear medicine oncology diagnosis and treatment sector, generating a record revenue of HKD 420 million, reflecting a year-on-year growth of nearly 106% [1][2] - The product Yttrium-90 microsphere injection (易甘泰®) continues to demonstrate strong market potential, maintaining rapid growth [1][2] - The company received early FDA approval for 易甘泰® for the treatment of unresectable hepatocellular carcinoma (HCC), becoming the first and only selective internal radiation therapy product approved for both unresectable HCC and colorectal cancer liver metastases [2] Innovative Products and Clinical Research - The company’s innovative product STC3141 for treating sepsis has successfully reached the endpoint of its Phase II clinical trial in China, representing a potential breakthrough in sepsis treatment [3] - STC3141 is the first global product aimed at re-establishing immune homeostasis for sepsis treatment, with clinical approvals obtained in five countries across three continents [3] - In the respiratory and critical care sectors, the company is advancing several innovative products, including nasal sprays and coenzyme Q10 tablets, which are expected to enhance commercial performance [4] Overall Growth and Competitive Advantage - The company has established a mature technological innovation development system, continuously reinforcing its differentiated advantages across various sectors [4] - The successful commercialization of innovative products is expected to provide ongoing development momentum, enhancing the company's core competitive advantages and creating value for investors [4]

Core Viewpoint - The stock price of Yuan Da Pharmaceutical (00512) has experienced a strong upward trend, achieving a four-day consecutive rise and over 20% increase within the week, driven by significant innovations in various fields [1]. Group 1: Innovations and Clinical Trials - The company has reached clinical endpoints in the Phase II trial of its innovative drug STC3141 for treating sepsis and has received acceptance for the Phase III clinical trial application of its radiopharmaceutical TLX591 for oncology [1][7]. - Yuan Da Pharmaceutical has a robust pipeline with 15 innovative products in the registration phase, covering multiple cancer types and offering integrated diagnostic and therapeutic solutions [3][5]. Group 2: Financial Performance - The nuclear medicine oncology segment is projected to generate approximately HKD 589 million in revenue for 2024, reflecting a year-on-year growth of nearly 177%, with the core product contributing nearly HKD 500 million [3]. - The company has seen its core product, Yttrium-90 microsphere injection, achieve over 140% year-on-year sales growth for two consecutive years [3]. Group 3: Strategic Developments - Yuan Da Pharmaceutical has established a comprehensive industrial layout, including R&D, production, sales, and regulatory qualifications, with a new radioactive drug R&D and production base in Chengdu expected to commence operations soon [6]. - The company is investing approximately HKD 3 billion in this facility, which aims to become a global hub for innovative nuclear medicine [6]. Group 4: Market Potential - The global market for sepsis treatment drugs is expected to grow from USD 12.54 billion in 2024 to USD 19.37 billion by 2032, with a compound annual growth rate of 5.58% [7]. - Yuan Da Pharmaceutical is positioned to fill a significant clinical gap in sepsis treatment with STC3141, which is anticipated to be a groundbreaking therapy [7]. Group 5: Eye Care Sector - The company has developed a comprehensive product system in the ophthalmology field, focusing on various eye diseases and has several innovative products in the pipeline [10][13]. - Yuan Da Pharmaceutical is recognized as a leader in the eye care sector, with a strong marketing network and a commitment to addressing unmet clinical needs [10][13].